Since thousands of women have received the RANKL blocking antibody Denosumab to treat osteoporosis thus highlighting its safety profile, we believe that targeting the RANKL/RANK pathway with Denosumab is indeed a feasible strategy for the prevention of breast cancer in BRCA1-mutation carriers and may also be effective for other women at high risk for developing breast cancer. This evidence concerns the gene TNFSF11 and breast cancer.